{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:50:59Z","timestamp":1790790659080,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":1080,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1111\/ajt.15495","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T11:57:00Z","timestamp":1560772620000},"page":"3223-3232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-6958","authenticated-orcid":false,"given":"Eric A.","family":"Engels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.15495_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol."},{"key":"10.1111\/ajt.15495_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","article-title":"Does the immune system naturally protect against cancer?","volume":"5","author":"Corthay","year":"2014","journal-title":"Front Immunol."},{"issue":"suppl","key":"10.1111\/ajt.15495_bib3","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol."},{"issue":"5023","key":"10.1111\/ajt.15495_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"BMJ."},{"issue":"5","key":"10.1111\/ajt.15495_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"issue":"6255","key":"10.1111\/ajt.15495_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.aab4082","article-title":"Somatic mutation in cancer and normal cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Science (New York, NY)."},{"issue":"11","key":"10.1111\/ajt.15495_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol."},{"issue":"1","key":"10.1111\/ajt.15495_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology."},{"issue":"7171","key":"10.1111\/ajt.15495_bib9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature."},{"issue":"6832","key":"10.1111\/ajt.15495_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature."},{"issue":"12","key":"10.1111\/ajt.15495_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"10.1111\/ajt.15495_bib12","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI82416","article-title":"Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes","volume":"125","author":"Cohen","year":"2015","journal-title":"J Clin Invest."},{"issue":"6184","key":"10.1111\/ajt.15495_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science (New York, NY)."},{"issue":"2","key":"10.1111\/ajt.15495_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","article-title":"Implications for immunosurveillance of altered HLA class I phenotypes in human tumours","volume":"18","author":"Garrido","year":"1997","journal-title":"Immunol Today."},{"issue":"11","key":"10.1111\/ajt.15495_bib15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nbt.3344","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","journal-title":"Nat Biotechnol."},{"issue":"7645","key":"10.1111\/ajt.15495_bib16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","year":"2017","journal-title":"Nature."},{"issue":"4","key":"10.1111\/ajt.15495_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"10.1111\/ajt.15495_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"10","key":"10.1111\/ajt.15495_bib19","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1084\/jem.20071190","article-title":"Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells","volume":"205","author":"Clark","year":"2008","journal-title":"J Exp Med."},{"key":"10.1111\/ajt.15495_bib20","series-title":"Janeway\u2019s Immunobiology","author":"Murphy","year":"2017"},{"issue":"26","key":"10.1111\/ajt.15495_bib21","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med."},{"issue":"7820","key":"10.1111\/ajt.15495_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(73)93256-X","article-title":"Risk of cancer in renal-transplant recipients","volume":"2","author":"Hoover","year":"1973","journal-title":"Lancet."},{"issue":"9581","key":"10.1111\/ajt.15495_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet."},{"issue":"17","key":"10.1111\/ajt.15495_bib24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA."},{"issue":"8","key":"10.1111\/ajt.15495_bib25","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15495_bib26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/bjc.2013.294","article-title":"Risk of lymphoma subtypes after solid organ transplantation in the United States","volume":"109","author":"Clarke","year":"2013","journal-title":"Br J Cancer."},{"issue":"2","key":"10.1111\/ajt.15495_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/ajt.14465","article-title":"Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients","volume":"18","author":"Mahale","year":"2018","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15495_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2015.08.014","article-title":"Immune control of oncogenic gamma-herpesviruses","volume":"14","author":"Jung","year":"2015","journal-title":"Curr Opin Virol."},{"issue":"2","key":"10.1111\/ajt.15495_bib29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: an update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer."},{"issue":"6","key":"10.1111\/ajt.15495_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MOT.0b013e3283186bbc","article-title":"Hypogammaglobulinemia and infection risk in solid organ transplant recipients","volume":"13","author":"Mawhorter","year":"2008","journal-title":"Curr Opin Organ Transplant."},{"issue":"4","key":"10.1111\/ajt.15495_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MOT.0b013e32833b9c38","article-title":"Clinical relevance of circulating donor-specific HLA antibodies","volume":"15","author":"Claas","year":"2010","journal-title":"Curr Opin Organ Transplant."},{"issue":"4","key":"10.1111\/ajt.15495_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nri2524","article-title":"B cells in HIV infection and disease","volume":"9","author":"Moir","year":"2009","journal-title":"Nat Rev Immunol."},{"issue":"5","key":"10.1111\/ajt.15495_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-157-5-201209040-00005","article-title":"U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008","volume":"157","author":"Althoff","year":"2012","journal-title":"Ann Intern Med."},{"issue":"11","key":"10.1111\/ajt.15495_bib34","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hernandez-Ramirez","year":"2017","journal-title":"Lancet HIV."},{"issue":"17","key":"10.1111\/ajt.15495_bib35","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1111\/ajt.15495_bib36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/ijc.27765","article-title":"Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008\u2013a Swedish population-based study","volume":"132","author":"Krynitz","year":"2013","journal-title":"Int J Cancer."},{"issue":"1","key":"10.1111\/ajt.15495_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjd.14153","article-title":"Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study","volume":"174","author":"Krynitz","year":"2016","journal-title":"Br J Dermatol."},{"issue":"11","key":"10.1111\/ajt.15495_bib38","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2015.1702","article-title":"Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study","volume":"151","author":"Levine","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"5","key":"10.1111\/ajt.15495_bib39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hed.25069","article-title":"Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: poor outcome unrelated to the index lesion","volume":"40","author":"Lam","year":"2018","journal-title":"Head Neck."},{"issue":"8","key":"10.1111\/ajt.15495_bib40","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/jid.2011.91","article-title":"Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma","volume":"131","author":"Arron","year":"2011","journal-title":"J Invest Dermatol."},{"issue":"5","key":"10.1111\/ajt.15495_bib41","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/ajt.14537","article-title":"Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: a multicenter, prospective cohort study","volume":"18","author":"Bouwes Bavinck","year":"2018","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15495_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0625.2011.01413.x","article-title":"Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair","volume":"21","author":"Kuschal","year":"2012","journal-title":"Exp Dermatol."},{"issue":"5742","key":"10.1111\/ajt.15495_bib43","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O\u2019Donovan","year":"2005","journal-title":"Science (New York, NY)."},{"issue":"1","key":"10.1111\/ajt.15495_bib44","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","article-title":"The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature","volume":"9","author":"Inman","year":"2018","journal-title":"Nat Commun."},{"issue":"7","key":"10.1111\/ajt.15495_bib45","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2014.77","article-title":"The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A","volume":"134","author":"Dziunycz","year":"2014","journal-title":"J Invest Dermatol."},{"issue":"5","key":"10.1111\/ajt.15495_bib46","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djs529","article-title":"HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer","volume":"105","author":"Silverberg","year":"2013","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"10.1111\/ajt.15495_bib47","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/ajt.15181","article-title":"Risk of lung cancer in lung transplant recipients in the United States","volume":"19","author":"Triplette","year":"2019","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15495_bib48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14737140.8.4.605","article-title":"Inflammation in the development of lung cancer: epidemiological evidence","volume":"8","author":"Engels","year":"2008","journal-title":"Expert Rev Anticancer Ther."},{"issue":"9","key":"10.1111\/ajt.15495_bib49","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jnci\/djy010","article-title":"Risk of breast, prostate, and colorectal cancer diagnoses among HIV-infected individuals in the United States","volume":"110","author":"Coghill","year":"2018","journal-title":"J Natl Cancer Inst."},{"issue":"8","key":"10.1111\/ajt.15495_bib50","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood."},{"issue":"7","key":"10.1111\/ajt.15495_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/1055-9965.EPI-17-0003","article-title":"Spectrum of immune-related conditions associated with risk of keratinocyte cancers among elderly adults in the United States","volume":"26","author":"Yanik","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"8","key":"10.1111\/ajt.15495_bib52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/sj.bjc.6605306","article-title":"Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma","volume":"101","author":"Koljonen","year":"2009","journal-title":"Br J Cancer."},{"issue":"7","key":"10.1111\/ajt.15495_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer."},{"issue":"6","key":"10.1111\/ajt.15495_bib54","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival after cancer diagnosis among solid organ transplant recipients in the United States","volume":"125","author":"D\u2019Arcy","year":"2019","journal-title":"Cancer."},{"issue":"21","key":"10.1111\/ajt.15495_bib55","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J Clin Oncol."},{"issue":"31","key":"10.1111\/ajt.15495_bib56","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2016.67.9613","article-title":"HIV infection and survival among women with cervical cancer","volume":"34","author":"Dryden-Peterson","year":"2016","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1111\/ajt.15495_bib57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/QAD.0000000000001367","article-title":"Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer","volume":"31","author":"Ferreira","year":"2017","journal-title":"AIDS."},{"issue":"5","key":"10.1111\/ajt.15495_bib58","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ndt\/17.5.892","article-title":"Successful treatment of post-transplant Kaposi\u2019s sarcoma by reduction of immunosuppression","volume":"17","author":"Duman","year":"2002","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"10.1111\/ajt.15495_bib59","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation."},{"issue":"8","key":"10.1111\/ajt.15495_bib60","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(10)70024-3","article-title":"Transmission of donor melanoma by organ transplantation","volume":"11","author":"Strauss","year":"2010","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1111\/ajt.15495_bib61","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol."},{"issue":"13","key":"10.1111\/ajt.15495_bib62","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"23","key":"10.1111\/ajt.15495_bib63","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1111\/ajt.15495_bib64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"25","key":"10.1111\/ajt.15495_bib65","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med."},{"issue":"7463","key":"10.1111\/ajt.15495_bib66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"issue":"4","key":"10.1111\/ajt.15495_bib67","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.15495_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"6230","key":"10.1111\/ajt.15495_bib69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science."},{"issue":"10064","key":"10.1111\/ajt.15495_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet."},{"issue":"2","key":"10.1111\/ajt.15495_bib71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet."},{"key":"10.1111\/ajt.15495_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","article-title":"DNA mismatch repair in cancer","volume":"189","author":"Baretti","year":"2018","journal-title":"Pharmacol Ther."},{"issue":"3","key":"10.1111\/ajt.15495_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer."},{"issue":"26","key":"10.1111\/ajt.15495_bib74","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1111\/ajt.15495_bib75","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1111\/ajt.15495_bib76","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-12): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1111\/ajt.15495_bib77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1111\/ajt.15495_bib78","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-15-1877","article-title":"UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas","volume":"75","author":"Wong","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1111\/ajt.15495_bib79","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djy060","article-title":"Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas","volume":"110","author":"Desrichard","year":"2018","journal-title":"J Natl Cancer Inst."},{"issue":"6334","key":"10.1111\/ajt.15495_bib80","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovic","year":"2017","journal-title":"Science (New York, NY)."},{"issue":"11","key":"10.1111\/ajt.15495_bib81","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/ijc.31735","article-title":"Risk of Kaposi sarcoma after solid organ transplantation in the United States","volume":"143","author":"Cahoon","year":"2018","journal-title":"Int J Cancer."},{"issue":"7","key":"10.1111\/ajt.15495_bib82","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ajh.23726","article-title":"Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States","volume":"89","author":"Gibson","year":"2014","journal-title":"Am J Hematol."},{"issue":"12","key":"10.1111\/ajt.15495_bib83","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1111\/ajt.12472","article-title":"HPV-related cancers after solid organ transplantation in the United States","volume":"13","author":"Madeleine","year":"2013","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.15495_bib84","doi-asserted-by":"crossref","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of merkel cell carcinoma after solid organ transplantation","volume":"107","author":"Clarke","year":"2015","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"10.1111\/ajt.15495_bib85","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/aje\/kwt153","article-title":"Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study","volume":"178","author":"Bertisch","year":"2013","journal-title":"Am J Epidemiol."},{"issue":"9","key":"10.1111\/ajt.15495_bib86","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet."},{"issue":"11","key":"10.1111\/ajt.15495_bib87","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/ng.3670","article-title":"Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors","volume":"48","author":"Middlebrooks","year":"2016","journal-title":"Nat Genet."},{"key":"10.1111\/ajt.15495_bib88","doi-asserted-by":"crossref","unstructured":"Adams S, Gatti-Mays ME, Kalinsky K, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7147. [Epub ahead of print].","DOI":"10.1001\/jamaoncol.2018.7147"},{"issue":"2","key":"10.1111\/ajt.15495_bib89","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol."},{"issue":"1","key":"10.1111\/ajt.15495_bib90","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"8","key":"10.1111\/ajt.15495_bib91","first-page":"379","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J Immunother (Hagerstown, MD: 1997)."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15495","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15495","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522093224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522093224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:25:49Z","timestamp":1761629149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522093224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1600613522093224"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15495","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}